At the IGTP TODAY

News

The autonomous ventilation device (DAR) developed by the Hospital Clínic Barcelona, Germans Trias i Pujol, the University of Barcelona and GASN2 is authorized by the AEMPS to start clinical trials

The Spanish Agency of Medicines and Medical Devices (AEMPS) has today given the green light to test the device developed by the company GasN2 with the support of professionals from the Hospital Clínic Barcelona, the Germans Trias i Pujol Research Institute (IGTP) and the University of Barcelona (UB). The prototype uses a system of electro pneumatic valves to supply and control the volume of oxygen necessary for each patient. Support from civil society, companies and administrations has been key to the development of the design and industrial scaling up of the model to contribute to the provision of the ventilators needed by the health system.

Two projects at the IGTP and IDIAP Jordi Gol research centres focus on the immune response of health professionals to infection with SARS-CoV-2

The IGTP has received funding in the extraordinary call published by the Department of Research and Innovation of the Department of Health (DGRIS) with the collaboration of AQuAS and Biocat and aimed at all the Iriscat centres for research into coronavirus. The two projects, focussed on the immune response of health professionals on the frontline with the virus, have joined the forces of the IGTP, IrsiCaixa and research and healthcare in the context of primary and hospital healthcare. A third project, led by Dr Julià Blanco, researcher at IrsiCaixa and the IGTP has also received funding.

Respira, the new ventilator device developed gets the go ahead from the AEMPS for clinical trials

The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved a clinical trial with the ventilation device RESPIRA developed by GAPInnova with the support of professionals from the Hospital Clínic Barcelona, the Germans Trias I Pujol Research Institute and the University of Barcelona. This is the second device developed with the support of these organizations to be approved by the AEMPS for testing on patients at the Hospital Clinic Barcelona and at Can Ruti. The prototype of the RESPIRA device mechanizes manual ressusitations with AMBU devices providing automatic respiration assistance and monitoring.

The IGTP is working to respond to COVID-19

The Germans Trias I Pujol Research Institute (IGTP) is working alongside the hospital and at the service of the Ministry of Health of the Government of Catalonia to make all the necessary disposable material and resources available for the diagnosis and treatment of COVID-19. The research groups at the centre are also working against the clock to prepare projects for the extraordinary competitive funding calls that have been issued to fund research into SARS-CoV-2 and the disease COVID-19.

- Campus Can Ruti, Research

New European initiative, RECOGNISED, will determine the usefulness of the retina as a tool for identifying people with type 2 diabetes and cognitive impairment

The IGTP is participating in this recently launched EU-funded project to explore the biological pathways that may link the alterations observed in the retina with those present in the brain in people with type 2 diabetes (T2D). In this way, the RECOGNISED project hopes to use the eye as if it was a window into the brain.

- Campus Can Ruti, Research

A team at Germans Trias treat a patient with a new bio-implant to repair heart tissue after a heart attack

The pioneering surgery that took place last May at the Germans Trias Hospital. The bio-implant, based on umbilical cord stem cells, has been developed by the Cardiovascular Disease Research Group (ICREC) at Germans Trias, led by Antoni Bayés-Genís in a research line, which they have been pursuing for 10 years. The new therapy has been developed with the collaboration of the Blood and Tissue Bank (BST) and the Institute of Bioengineering of Catalonia (IBEC); this is the first step of the application in clinical practice and the group will continue to monitor safety and the capacity of cardiac tissue to recover

Germans Trias Professionals organize the first National Meeting on Neurofibromatosis Type 2

Last Friday the first update meeting at national level to take a global view of the healthcare situation and present the latest research data for Neurofibromatosis type 2 (NF2) took place at the IGTP. This pioneering event was organized by the members of the National Reference Centre in genetic neuro-cutaneous syndromes (Facomatosis), (CSUR) on the Can Ruti Campus and also included patients and families affected by the disease.

The IGTP promotes science for high-school students at the celebration of the 24th Science Week at Can Ruti

This week the IGTP and other centres hosted the “Can Ruti Open Door Session” within Science Week in Badalona; the Science Week is a national event organized by the Spanish Foundation for Science and Technology (FECYT). This year nearly 200 high school students from various educational centres have visited the research facilities at nine different organizations on the Can Ruti Campus and learned about studies taking place there.

The Comparative Medicine and Bioimaging Centre (CMCiB) opens its new facilities for research with bioimage

The Director of the Germans Trias i Pujol Research Institute (IGTP), Manel Puig, and the President of the Canon Medical Systems Corporation (Canon Medical), Toshio Takiguchi, visited the CMCiB on Monday 14 October to view the new bioimaging facilities that complete the center as a pioneering research platform in comparative medicine. The CMCiB, a center promoted by the IGTP and a benchmark in comparative medicine, bioimaging and computational models, is a pioneer in the application of alternative methods of biomedical research that directly affect the improvement of people's health.